IMR Press CEOG EJGO JIN RCM JOMH JMCM BRI

Special Issues

Special Issue Title: BRCA and Ovarian Cancer

· Print Special Issue Flyer

· Deadline for manuscript submissions:  30 April 2021

Special Issue Editor

Guest Editor


              Prof. Dr. Gennaro Cormio

              University of Bari, Italy

Website | E-Mail

Interests: Vulvar Cancer; Ovarian Cancer

Special Issue Information

Dear Colleagues,


Ovarian cancer is the fifth cause of cancer death in women worldrwide. The role of BRCA 1-1 genes mutation ha resulted in a significant improvement in scientific research in this field. Brca mutation has been reported in about 15 to 30 % of ovarian cancer patients in different geographic areas. It has a probably a prognostic role but particularly a fundamental predictive role of response to PARP inhibitors and may be also other compounds. A number of researches are actually ongoing in order to confirm the potential role of this mutation in surgical and medical management of ovarian cancer. Moreover the role of BRCA gene mutation detection in the general population is fundamental in order to achieve a potential genetic prevention of ovarian cancer. A number of potential strategies are studied also concerning reproductive medicine and BRCA 1-2 mutation. The aim of this special issue of the Journal is to collect new insights on this fascinating topic.


Prof. Dr. Gennaro Cormio

Guest Editor

 

Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.


Keywords

BRCA 1-2 Mutation; Ovarian Cancer; Prophylactic Surgery; Reproductive Medicine; Hormonal Treatment


Share This Special Issue

     



Please wait a minute...
For Selected: Toggle Thumbnails
BRCA-guided therapy of ovarian cancer
Panagiota Economopoulou, Ioannis Kotsantis, Aristotelis Bamias
European Journal of Gynaecological Oncology    2021, 42 (3): 405-413.   DOI: 10.31083/j.ejgo.2021.03.2210
Abstract （370）   HTML （41）    PDF（pc） （152KB）（276）       Save

Advanced (FIGO stages III and IV) epithelial ovarian cancer (aEOC) accounts for the majority of deaths from gynecological cancers in western countries. Although the prognosis of this disease has been considerably improved in the last two decades, the majority of women will still die from progression of EOC. Optimal cytoreductive surgery and cytotoxic chemotherapy remains the mainstay of treatment in the front-line setting. Approximately 18% of EOCs harbor germline mutations of the tumor suppressor genes Breast Cancer Susceptibility Gene 1 (BRCA1) and 2 (BRCA2), while another 3–6% of these tumors have somatic mutations of these genes. These mutations lead to increased predisposition of multiple cancers. In addition, BRCA1 and BRCA2 genes encode proteins that are implicated in the Homologous Recombination (HR) mechanism, which is responsible for the repair of DNA Double Strand Breaks (DSBs), which is a common mechanism of action of chemotherapy. The incorporation of BRCA-targeted therapies, such as poly ADP ribose polymerase (PARP) inhibitors in the treatment algorithm of advanced EOC has further improved outcomes and represents a successful strategy of individualization of treatment in EOC. In this review, we summarize current treatment recommendations for patients with EOC and a BRCA1/2 mutation.
Related Articles | Metrics
Prophylactic mastectomy and ovariectomy—a religious perspective
Bartosz Kasprzak, Przemysław Zgórecki
European Journal of Gynaecological Oncology    2021, 42 (3): 414-417.   DOI: 10.31083/j.ejgo.2021.03.2253
Abstract （362）   HTML （21）    PDF（pc） （107KB）（134）       Save

Prophylactic mastectomy and ovariectomy doesn't seem to be a religious problem at first, therefore not much research on the subject has been done so far. As the awareness of the problem of breast and ovarian cancer threat and subsequently of the issue of prophylactic procedures for BRCA carriers is growing among general public, it is worth to ask the question if and in what way religion itself as well as religious communities may help. The article explores the impact of religious perspective on both physicians and patients as they face these problems. The issue is discussed from physicians' and chaplains' perspective. In the context of this discussion the question of involvement of religious communities in providing better information and support to patients-members of these communities is asked. The aim of the research done here is to open discussion on the possibility of providing better medical and spiritual help, with greater respect and empathy to every patient, no matter their religious and/or cultural background, by involving religious perspective in the process.
Related Articles | Metrics
Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice
Chiara Cassani, Francesca Zanellini, Cristina Angela Camnasio, Diana Pettinato, Simona Secondino, Angelica Della Valle, Mario Urtis, Eloisa Arbustini, Silvia Martella, Arsenio Spinillo, Rossella Elena Nappi
European Journal of Gynaecological Oncology    2021, 42 (3): 441-449.   DOI: 10.31083/j.ejgo.2021.03.2281
Abstract （225）   HTML （30）    PDF（pc） （143KB）（145）       Save

The objective of this narrative review is to put risks and benefits for the use of oral contraception (OC) into perspective in counselling high-risk carriers of BRCA1 or BRCA2 gene mutations. We searched PubMed, Embase, and the Cochrane Library for studies that evaluated associations between OC use and breast or ovarian cancer among women who are carriers of BRCA1/2 mutations. All studies concordantly demonstrated an inverse correlation between OC and ovarian cancer risk in BRCA mutated women. Regarding breast cancer risk, results are conflicting with some studies reporting a slightly increased risk associated with OC use, whereas others reveal no evidence of a significant association in carriers. Numerous potential cancer risk modifiers and the modern evolution of OC can partly explain these results. OC use may also reduce the risk of extra-ovarian cancers such as those of the colon and endometrium, as observed in the general population. BRCA1/2 carriers should always receive a sensible and patient-centered contraceptive counselling because current evidence does not support recommendation against OC use, taking into account the individual profile.
Related Articles | Metrics
New treatment strategy for ovarian cancer with a BRCA gene mutation
Tadahiro Shoji, Kotoka Kikuchi, Hayato Kogita, Nanako Jonai, Hidetoshi Tomabechi, Akiko Kudoh, Eriko Takatori, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba
European Journal of Gynaecological Oncology    2021, 42 (1): 1-9.   DOI: 10.31083/j.ejgo.2021.01.2251
Abstract （454）   HTML （75）    PDF（pc） （335KB）（336）       Save

Mutated BRCA1/2 genes have been identified as causative genes for ovarian cancer, and it has been reported that 10–20% of all epithelial ovarian cancers have a BRCA mutation. As novel treatment drugs utilizing this BRCA gene mutation, significant attention has been paid to adenine dinucleotide poly (ADP-ribose) polymerase inhibitors. Among them, olaparib has been reported to be useful in patients with a BRCA mutation in Study 19 and SOLO-2 trials. It is important to establish a system for genetic counseling and to perform BRCA gene testing in patients with ovarian cancer. For patients with BRCA -mutated advanced cancer, if adequate response to chemotherapy has been achieved, olaparib is recommended as maintenance therapy for both advanced and recurrent cases. For patients without BRCA gene mutation, bevacizumab combined with chemotherapy or as maintenance therapy is also an option.
Related Articles | Metrics

Current Issue

  • Volume 42, Issue 5
Submit  to  EJGO
ABOUT
EJGO
Editorial board
Subscriptions
Contact us
ARTICLES
Current issue
Archive
Alerts
RSS feeds
INFO FOR
Author instructions
Reviewer instructions
Reference style & template
Print ISSN: 0392-2936
Online ISSN: 2709-0086
Copyright © 2021 IMR Press.